Margetuximab Approved for HER2+ Metastatic Breast Cancer Margetuximab Approved for HER2+ Metastatic Breast Cancer

A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news